Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Renal-sparing immunosuppressive protocol using OKT3 after liver transplantation: a 19-year single-institution experience.

Kim PT, Chinnakotla S, Davis G, Jennings LW, McKenna GJ, Onaca N, Ruiz RM, Goldstein R, Levy MF, Klintmalm GB.

Proc (Bayl Univ Med Cent). 2011 Oct;24(4):287-94.

2.

Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation.

Rosen HR, Shackleton CR, Higa L, Gralnek IM, Farmer DA, McDiarmid SV, Holt C, Lewin KJ, Busuttil RW, Martin P.

Am J Gastroenterol. 1997 Sep;92(9):1453-7.

PMID:
9317061
3.

A randomized trial of OKT3-based versus cyclosporine-based immunoprophylaxis after liver transplantation. Long-term results of a European and Australian multicenter study.

Farges O, Ericzon BG, Bresson-Hadni S, Lynch SV, Höckerstedt K, Houssin D, Galmarini D, Faure JL, Baldauf C, Bismuth H.

Transplantation. 1994 Oct 27;58(8):891-8.

PMID:
7940732
4.

OKT3 salvage therapy in a quadruple immunosuppressive protocol in cadaveric renal transplantation.

D'Alessandro AM, Pirsch JD, Stratta RJ, Sollinger HW, Kalayoglu M, Maki DG, Belzer FO.

Transplantation. 1989 Feb;47(2):297-300.

PMID:
2493176
5.

Induction immunosuppression with antilymphocyte globulin or OKT3 in cadaver kidney transplantation. Results of a single institution prospective randomized trial.

Hanto DW, Jendrisak MD, So SK, McCullough CS, Rush TM, Michalski SM, Phelan D, Mohanakumar T.

Transplantation. 1994 Feb;57(3):377-84.

PMID:
8108873
6.

OKT3 induction and steroid-free maintenance immunosuppression for treatment of high-risk heart transplant recipients.

Prieto M, Lake KD, Pritzker MR, Jorgensen CR, Arom KV, Love KR, Emery RW.

J Heart Lung Transplant. 1991 Nov-Dec;10(6):901-11.

PMID:
1661608
7.

OKT3 (muromonab-CD3) associated hepatitis in a kidney transplant recipient.

Go MR, Bumgardner GL.

Transplantation. 2002 Jun 27;73(12):1957-9.

PMID:
12131696
8.

Acute renal failure in critically ill surgical patients: persistent lethality despite new modes of renal replacement therapy.

Eachempati SR, Wang JC, Hydo LJ, Shou J, Barie PS.

J Trauma. 2007 Nov;63(5):987-93.

PMID:
17993940
9.

Selective OKT3 induction therapy in adult cadaveric-donor renal transplant recipients.

Thistlethwaite JR Jr, Heffron TG, Stuart JK, Buckingham M, Stuart FP.

Am J Kidney Dis. 1989 Nov;14(5 Suppl 2):28-34.

PMID:
2510508
10.

A non-induction renal sparing approach after liver transplantation: high dose mycophenolate mofetil with delayed, low-dose tacrolimus.

Rao V, Haywood S, Abecassis M, Levitsky J.

Transplant Proc. 2013 Jan-Feb;45(1):320-2. doi: 10.1016/j.transproceed.2012.06.062. Epub 2012 Sep 19.

PMID:
23267806
11.

Basiliximab plus low-dose cyclosporin vs. OKT3 for induction immunosuppression following renal transplantation.

Kode R, Fa K, Chowdhury S, Ranganna K, Fyfe B, Stabler S, Damask A, Laftavi MR, Kumar AM, Pankewycz O.

Clin Transplant. 2003 Aug;17(4):369-76.

PMID:
12868995
12.

Prophylactic use of OKT3 in immunologic high-risk cadaver renal transplant recipients.

Schroeder TJ, First MR, Mansour ME, Alexander JW, Penn I.

Am J Kidney Dis. 1989 Nov;14(5 Suppl 2):14-8.

PMID:
2510506
13.

Survival of liver transplant candidates with acute renal failure receiving renal replacement therapy.

Wong LP, Blackley MP, Andreoni KA, Chin H, Falk RJ, Klemmer PJ.

Kidney Int. 2005 Jul;68(1):362-70.

14.

A randomized prospective trial of low-dose OKT3 induction therapy to prevent rejection and minimize side effects in recipients of kidney transplants.

Flechner SM, Goldfarb DA, Fairchild R, Modlin CS, Fisher R, Mastroianni B, Boparai N, O'Malley KJ, Cook DJ, Novick AC.

Transplantation. 2000 Jun 15;69(11):2374-81.

PMID:
10868643
15.
16.

OKT3 escalating dose regimens provide effective therapy for renal allograft rejection.

Woodle ES, Bruce DS, Josephson M, Cronin D, Newell KA, Millis JM, Piper JB, O'Laughlin R, Thistlethwaite JR Jr.

Clin Transplant. 1996 Aug;10(4):389-95.

PMID:
8884115
17.

OKT3 rescue for steroid-resistant rejection in adult liver transplantation.

Solomon H, Gonwa TA, Mor E, Holman MJ, Gibbs J, Watemberg I, Netto G, Goldstein RM, Husberg BS, Klintmalm GB.

Transplantation. 1993 Jan;55(1):87-91.

PMID:
8420070
18.
19.

Influence of low-dose cyclosporine on the outcome of treatment with OKT3 for acute renal allograft rejection.

Hricik DE, Zarconi J, Schulak JA.

Transplantation. 1989 Feb;47(2):272-7.

PMID:
2493175
20.

A randomized prospective trial of prophylactic immunosuppression with ATG-fresenius versus OKT3 after renal transplantation.

Bock HA, Gallati H, Zürcher RM, Bachofen M, Mihatsch MJ, Landmann J, Thiel G.

Transplantation. 1995 Mar 27;59(6):830-40.

PMID:
7701577

Supplemental Content

Support Center